Zhengye Biotechnology Holding Limited (Stock Code: ZYBT)—with Jilin Zhengye Biological Products Co., Ltd. serving as its primary domestic operating entity—officially began trading on the Nasdaq exchange at 10:45 AM Eastern Time on January 7 (11:45 PM Beijing Time on January 7). This marks the first US IPO in China's animal health industry and the first Nasdaq listing for a company from Jilin Province. The company offered 1.5 million shares of common stock at a public offering price of $4.00 per share, with a total share capital of 47.1664 million shares. Proceeds from the offering will be used to acquire vaccine manufacturing companies and fund research and development projects.

Jilin Zhengye Biological Products Co., Ltd. is an animal vaccine manufacturer specializing in the R&D, production, sales, and technical services associated with animal vaccines. Located in Jilin City, Jilin Province—known as the "River City" of the north—the company traces its origins to the Harbin Veterinary Biological Products Factory under the Ministry of Agriculture. It relocated to Jilin City in 1970 and boasts a history spanning over 50 years. Reorganized from the Jilin Provincial Biological Products Factory in 2004, it is now a privately controlled joint-stock enterprise. The company operates 14 GMP-certified production lines, including those for cell suspension culture and genetically engineered vaccines. Its product portfolio covers vaccines for four categories—swine, poultry, ruminants (cattle and sheep), and pets—comprising over 40 product registration numbers and more than 80 product specifications. Its animal testing center, which became operational in October 2015, features an intelligent testing and analysis platform capable of simultaneously conducting various animal trials and quality assessments for vaccine products.

Several of the company's poultry vaccines have been successfully exported to countries such as Egypt, Pakistan, and Vietnam. In April 2020, the company was honored with the title of "Demonstration Enterprise for the Export of Veterinary Biological Products in Jilin Province."

With the mission of "Making Life Better for Animals through Technology," the Company prioritizes technological innovation and R&D investment. It has been recognized as a National High-Tech Enterprise for consecutive years. Key milestones include: approval to establish the "Jilin Province Animal Vaccine Engineering Research Center" in April 2021; recognition as a Jilin Provincial "Specialized, Refined, Differential, and Innovative" (SRDI) SME in August 2022; approval to prepare for the establishment of the "Jilin Province Animal Vaccine Technology Innovation Center" in August 2023; receipt of the "Top 100 Private Enterprises in Jilin City" honor from the Jilin City Party Committee and Municipal Government in both 2021 and 2022; approval to jointly build the "Novel Vaccine Adjuvant R&D Technology Innovation Laboratory" with Jilin Medical University in December 2023; and approval to prepare for the establishment of the "Jilin Province Pet Vaccine Key Laboratory" in September 2024. In November 2024, following the public announcement of the first batch of proposed "Scientist Studios" in Jilin Province for 2024, Zhengye Bio was approved to establish the "Jilin Province Zhengye Animal Poxvirus Vaccine Scientist Studio."

For more information, please visit the company's website at http://ir.jlzybio.com.

Kingswood Capital Partners, LLC ("Kingswood") is acting as the sole bookrunner for this offering. Hunter Taubman Fischer & Li LLC is serving as U.S. securities legal counsel to the Company, and VCL Law LLP is serving as U.S. legal counsel to Kingswood in connection with this offering.